Annual CFO
-$19.81 M
+$5.06 M+20.34%
31 December 2023
Summary:
Aileron Therapeutics annual cash flow from operations is currently -$19.81 million, with the most recent change of +$5.06 million (+20.34%) on 31 December 2023. During the last 3 years, it has risen by +$668.00 thousand (+3.26%). ALRN annual CFO is now -69.15% below its all-time high of -$11.71 million, reached on 31 December 2015.ALRN Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFO
-$3.82 M
+$4.57 M+54.48%
30 September 2024
Summary:
Aileron Therapeutics quarterly cash flow from operations is currently -$3.82 million, with the most recent change of +$4.57 million (+54.48%) on 30 September 2024. Over the past year, it has dropped by -$2.18 million (-132.87%). ALRN quarterly CFO is now -132.87% below its all-time high of -$1.64 million, reached on 30 September 2023.ALRN Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFO
-$27.87 M
-$2.18 M-8.48%
30 September 2024
Summary:
Aileron Therapeutics TTM cash flow from operations is currently -$27.87 million, with the most recent change of -$2.18 million (-8.48%) on 30 September 2024. Over the past year, it has dropped by -$14.04 million (-101.58%). ALRN TTM CFO is now -643.60% below its all-time high of -$3.75 million, reached on 31 March 2016.ALRN TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
ALRN Cash From Operations Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +20.3% | -132.9% | -101.6% |
| 3 y3 years | +3.3% | +47.4% | -25.6% |
| 5 y5 years | +29.1% | +45.3% | -3.9% |
ALRN Cash From Operations High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | at high | +20.3% | -132.9% | +63.3% | -101.6% | at low |
| 5 y | 5 years | at high | +29.1% | -132.9% | +63.3% | -101.6% | at low |
| alltime | all time | -69.2% | +29.1% | -132.9% | +63.3% | -643.6% | +2.2% |
Aileron Therapeutics Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$3.82 M(-54.5%) | -$27.87 M(+8.5%) |
| June 2024 | - | -$8.39 M(+59.2%) | -$25.69 M(+25.8%) |
| Mar 2024 | - | -$5.27 M(-49.3%) | -$20.42 M(+3.1%) |
| Dec 2023 | -$19.81 M(-20.3%) | -$10.39 M(+533.6%) | -$19.81 M(+43.3%) |
| Sept 2023 | - | -$1.64 M(-47.4%) | -$13.83 M(-27.8%) |
| June 2023 | - | -$3.12 M(-33.1%) | -$19.16 M(-11.8%) |
| Mar 2023 | - | -$4.66 M(+5.7%) | -$21.73 M(-12.6%) |
| Dec 2022 | -$24.86 M(+4.7%) | -$4.41 M(-36.8%) | -$24.86 M(-6.9%) |
| Sept 2022 | - | -$6.97 M(+22.6%) | -$26.71 M(-1.1%) |
| June 2022 | - | -$5.68 M(-27.1%) | -$27.00 M(+7.7%) |
| Mar 2022 | - | -$7.80 M(+24.7%) | -$25.08 M(+5.6%) |
| Dec 2021 | -$23.75 M(+16.0%) | -$6.25 M(-13.8%) | -$23.75 M(+7.1%) |
| Sept 2021 | - | -$7.26 M(+92.9%) | -$22.19 M(+11.1%) |
| June 2021 | - | -$3.76 M(-41.9%) | -$19.97 M(-6.2%) |
| Mar 2021 | - | -$6.48 M(+38.1%) | -$21.28 M(+3.9%) |
| Dec 2020 | -$20.48 M | -$4.69 M(-7.0%) | -$20.48 M(-7.3%) |
| Sept 2020 | - | -$5.04 M(-0.6%) | -$22.09 M(-8.0%) |
| June 2020 | - | -$5.07 M(-10.6%) | -$24.02 M(-2.5%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2020 | - | -$5.67 M(-10.0%) | -$24.64 M(-6.9%) |
| Dec 2019 | -$26.47 M(-5.2%) | -$6.30 M(-9.6%) | -$26.47 M(-1.3%) |
| Sept 2019 | - | -$6.98 M(+22.6%) | -$26.83 M(+0.4%) |
| June 2019 | - | -$5.69 M(-24.1%) | -$26.73 M(-6.2%) |
| Mar 2019 | - | -$7.50 M(+12.6%) | -$28.50 M(+2.0%) |
| Dec 2018 | -$27.93 M(+36.0%) | -$6.66 M(-3.1%) | -$27.93 M(+3.0%) |
| Sept 2018 | - | -$6.88 M(-7.8%) | -$27.10 M(+6.4%) |
| June 2018 | - | -$7.46 M(+7.6%) | -$25.46 M(+18.4%) |
| Mar 2018 | - | -$6.93 M(+18.7%) | -$21.51 M(+4.8%) |
| Dec 2017 | -$20.53 M(+36.7%) | -$5.84 M(+11.5%) | -$20.53 M(+8.5%) |
| Sept 2017 | - | -$5.24 M(+49.4%) | -$18.93 M(+7.4%) |
| June 2017 | - | -$3.50 M(-41.1%) | -$17.62 M(+2.3%) |
| Mar 2017 | - | -$5.95 M(+40.6%) | -$17.22 M(+14.7%) |
| Dec 2016 | -$15.01 M(+28.2%) | -$4.23 M(+7.8%) | -$15.01 M(+39.3%) |
| Sept 2016 | - | -$3.93 M(+26.4%) | -$10.78 M(+57.3%) |
| June 2016 | - | -$3.11 M(-17.1%) | -$6.86 M(+82.9%) |
| Mar 2016 | - | -$3.75 M | -$3.75 M |
| Dec 2015 | -$11.71 M | - | - |
FAQ
- What is Aileron Therapeutics annual cash flow from operations?
- What is the all time high annual CFO for Aileron Therapeutics?
- What is Aileron Therapeutics annual CFO year-on-year change?
- What is Aileron Therapeutics quarterly cash flow from operations?
- What is the all time high quarterly CFO for Aileron Therapeutics?
- What is Aileron Therapeutics quarterly CFO year-on-year change?
- What is Aileron Therapeutics TTM cash flow from operations?
- What is the all time high TTM CFO for Aileron Therapeutics?
- What is Aileron Therapeutics TTM CFO year-on-year change?
What is Aileron Therapeutics annual cash flow from operations?
The current annual CFO of ALRN is -$19.81 M
What is the all time high annual CFO for Aileron Therapeutics?
Aileron Therapeutics all-time high annual cash flow from operations is -$11.71 M
What is Aileron Therapeutics annual CFO year-on-year change?
Over the past year, ALRN annual cash flow from operations has changed by +$5.06 M (+20.34%)
What is Aileron Therapeutics quarterly cash flow from operations?
The current quarterly CFO of ALRN is -$3.82 M
What is the all time high quarterly CFO for Aileron Therapeutics?
Aileron Therapeutics all-time high quarterly cash flow from operations is -$1.64 M
What is Aileron Therapeutics quarterly CFO year-on-year change?
Over the past year, ALRN quarterly cash flow from operations has changed by -$2.18 M (-132.87%)
What is Aileron Therapeutics TTM cash flow from operations?
The current TTM CFO of ALRN is -$27.87 M
What is the all time high TTM CFO for Aileron Therapeutics?
Aileron Therapeutics all-time high TTM cash flow from operations is -$3.75 M
What is Aileron Therapeutics TTM CFO year-on-year change?
Over the past year, ALRN TTM cash flow from operations has changed by -$14.04 M (-101.58%)